SCHEMBL857950

SCHEMBL857950

CCCOc1ccc2ncn[c]c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.40
GPBAR1 Q8TDU6 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
FGFR1 P11362 1/20 0.39
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
HIF1A Q16665 1/20 0.38
NCF1 P14598 4/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
MAPT P10636 2/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856553 0.87 MAP4K4 (0.43) LTA4HLMNAMAPK1HIF1ACA12
SCHEMBL855777 0.86 FBP1 (0.42) FGFR1NCF1
SCHEMBL622641 0.69 FGFR1 (0.48) LTA4HGPBAR1CYSLTR1FGFR1LMNA
SCHEMBL22325684 0.67 CA12 (0.59) LTA4HGPBAR1CYSLTR1MAPK1NCF1
SCHEMBL855315 0.67 EGFR (0.49) FGFR1LMNANCF1MAPTKMT2A
SCHEMBL3137746 0.67 CA12 (0.41) LTA4HFGFR1LMNACA12CA1
SCHEMBL15404712 0.67 ENPP1 (0.43) LMNA
1,4-Dipropoxybenzene SCHEMBL122039 0.66 LTA4H (0.67) LTA4HLMNAMAPK1CA12CA1
SCHEMBL2441527 0.66 MAPK1 (0.40) LTA4HLMNAMAPK1HIF1ACA12
SCHEMBL9723672 0.65 LTA4H (0.79) LTA4HLMNAMAPK1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA LTA4H 802/4885GPBAR1 2226/4885CYSLTR1 3002/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA LTA4H 903/4885GPBAR1 2232/4885CYSLTR1 3295/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA LTA4H 705/4885GPBAR1 2323/4885CYSLTR1 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.